MYDX - MyDx, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0022
-0.0002 (-8.33%)
At close: 3:52PM EST
Stock chart is not supported by your current browser
Previous Close0.0024
Open0.0000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume3,259,244
Market Cap8.591M
Beta (3Y Monthly)-3.08
PE Ratio (TTM)N/A
EPS (TTM)-0.0020
Earnings DateNov 24, 2017 - Nov 27, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire2 months ago

    MYDX RECRUITS MR. CANNABIS GROUP TO OPERATE COMPANY

    MyDx, Inc. (OTC: MYDX) (the “Company”), a leader in science based cannabis health technologies, is proud to announce that it has successfully recruited the Mr. Cannabis Group to operate the Company effective immediately. Mr. Beckmann is an accomplished thought leader and influencer in the southern California cannabis industry, and is recognized as “Mr. Cannabis”.  In 2015, Erai helped federally legalize medical THC and CBD in the country of Brazil.  Since then, he has advised major pharma groups to help them with their global CBD R&D efforts.  As a result of his work with big pharma, and his own cannabis lobbying experience in Latin America, he co-founded Humanity, Inc., which believes it will produce the world’s first nootropics-infused microdosed cannabis pill.

  • MyDx Analyzer to be Used in Large HIV Study by the University of Florida
    Newsfile4 months ago

    MyDx Analyzer to be Used in Large HIV Study by the University of Florida

    San Diego, California--(Newsfile Corp. - September 28, 2018) - MyDx, Inc. (OTC Pink: MYDX), a leader in science based cannabis health technologies, is proud to announce that the University of Florida will be using our flagship product, the CannaDx Analyzer, in the largest prospective study to date focused on the health effects of marijuana in people living with HIV.MyDx Analyzer to be Used in Large HIV Study Please visit http://orders.newsfilecorp.com/files/6086/38974_a1538137879405_91.jpg to view this image"With this study, we ...

  • Newsfile4 months ago

    MyDx Shareholder Update

    A Leader in Science-Based Cannabis Health Technologies Positioning for a Pharma Acquisition San Diego, California--(Newsfile Corp. - September 21, 2018) - MyDx, Inc. (OTC Pink: MYDX), a leader in science-based cannabis health technologies, has been working diligently over the past four months on implementing a strategy designed to have it become a highly desired acquisition target for big pharma or another entity interested in the powerful data MyDx is accumulating in the emerging global ...

  • Newsfile4 months ago

    MyDx Announces 2018 First Quarter Results

    MyDx Reports Positive Net Income as it Positions Itself for Growth and Investment San Diego, California--(Newsfile Corp. - September 19, 2018) - MyDx, Inc. (OTC Pink: MYDX), a leader in science based cannabis health technologies and creator of the industry's first handheld analyzer to help consumers and professionals understand how cannabis makes cannabis users feel,today announces its 2018 first quarter earnings results and management analysis.MyDx reported positive earnings of $880k in the first quarter of 2018 as it ...

  • MyDx Secures City and State Legal Cannabis Manufacturing and Distribution for Its MyDx360 Customers
    Newsfile4 months ago

    MyDx Secures City and State Legal Cannabis Manufacturing and Distribution for Its MyDx360 Customers

    MyDx360 Customers in California Now Have Access to One of the First Legally Licensed Cannabis Manufacturing and Distribution Facilities Located in the City of San Diego San Diego, California--(Newsfile Corp. - September 19, 2018) - MyDx, Inc. (OTC Pink: MYDX) ("MyDx" or the "Company"), a leader in science based cannabis health technologies and creator of the industry's first handheld, multi-use chemical analyzer to help consumers and professionals understand how cannabis makes cannabis users feel, announced ...

  • Newsfile4 months ago

    Dr. Heiner Dreismann, Former CEO of Roche Molecular Systems and Diagnostics Veteran, Joins MyDx Executive Advisory Board

    Dr. Dreismann To Also Serve as Chairman of the Executive Advisory Board; Assist MyDx In Seeking Development Partners and Strategic Partners San Diego, California--(Newsfile Corp. - September 19, 2018) - MyDx, Inc. (OTC Pink: MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to understand the chemical profile of cannabis with how it makes them feel and which ailments it ...

  • Newsfile4 months ago

    MyDx Announces 2017 Fiscal Year Results

    Gross Profit Margin Surged to 73% with Gross Profits Remaining Relatively Flat at ~$306K as MyDx Continues to Execute on its Long-Term Strategy San Diego, California--(Newsfile Corp. - September 19, 2018) - MyDx, Inc. (OTC Pink: MYDX), a science and technology company and creator of MyDx® (My Diagnostic), the first multi-use handheld chemical analyzer designed for Cannabis professionals and retail consumers to correlate the chemical profile of cannabis with how it makes them feel and which ailments ...

  • The Biggest Lie In Cannabis
    CNW Group11 months ago

    The Biggest Lie In Cannabis

    The Biggest Lie In Cannabis

  • The Biggest Lie In Cannabis
    PR Newswire11 months ago

    The Biggest Lie In Cannabis

    MyDx entered into an agreement to provide a licensor with access to its dataset in order to come up with a "Counterfeit Index" that determines the likelihood that a strain name doesn't tie to its chemical profile. The counterfeit index will identify and rank the strain names that have the greatest deviation in chemical profile which is often the result of intentionally mislabeling strains with names that gain extreme popularity in order to yield a greater price per gram. Since popular names yield higher prices, the index plans to inform consumers to demand confirmation of the chemical profile to ensure they're getting what they paid for.